Objectives: Sulfamethoxazole/trimethoprim is standard therapy for infections caused by opportunist nonfermenters except Pseudomonas aeruginosa and Acinetobacter. Sulfametrol(e)/trimethoprim is an alternative to sulfamethoxazole/trimethoprim available in some EU countries, with possible pharmacological advantages. We compared their activities against (i) non-fermenters, (ii) multiresistant Enterobacteriaceae and (iii) reference strains with sul1 and sul2.
Introduction
Intravenous sulfamethoxazole/trimethoprim (also known as co-trimoxazole) is used extensively against Pneumocystis infection. It is also the treatment of choice against non-fermentative opportunists except Pseudomonas aeruginosa, which is inherently resistant, and Acinetobacter spp., where acquired resistance is widespread. Oral sulfamethoxazole/trimethoprim is used widely in community urinary tract infections, though trimethoprim alone is preferred in the UK following concern about sulfamethoxazole side effects in the 1980s. 1 Important non-fermenters targeted with sulfamethoxazole/trimethoprim include Stenotrophomonas maltophilia, Burkholderia cepacia group species, Chryseobacterium spp. and Elizabethkingia spp. (the last two species were previously both assigned to Flavobacterium), Achromobacter spp. and Alcaligenes spp. These organisms are inherently resistant to many other antibiotic classes, and sulfamethoxazole/trimethoprim is often the sole agent to remain active. 2 -4 Several species, notably S. maltophilia and Elizabethkingia meningoseptica, have chromosomally mediated carbapenemases. Intravenous sulfamethoxazole/trimethoprim is sometimes also used against Enterobacteriaceae infections, particularly for b-lactam-allergic patients, 5 but this use is constrained by resistance, largely mediated by plasmid-mediated dihydopteroate synthase and dihydrofolate reductase enzymes, Alcaligenes  sulfametrole  2  1  7  100  sulfamethoxazole  4   a   4  2  100  trimethoprim  1  2  1  1  5   b   10  sulfametrole/trimethoprim  2  5  3  100  sulfamethoxazole/  trimethoprim   1   a   6  3  100   ticarcillin/clavulanate  2  1  2  4  1  90  piperacillin/tazobactam  2  2  4  2  100  cefotaxime  2  4  2  1  1  100  imipenem  8  1  1  100  moxifloxacin  1  2  3  2  1  1   b   80  tigecycline  2  1  2  3  1  1  50   Burkholderia  sulfametrole  1  6  8  9  3  5  8  60  sulfamethoxazole  1  2 16  2  3  10  1  5  60  trimethoprim  1  1  3  7 12 4  2  2  2  2  4   b   70  sulfametrole/trimethoprim  1  2  9 15  3  3  3  4  75  sulfamethoxazole/  trimethoprim   1  4  12 11  2  3  4  3  75   ticarcillin/clavulanate  1  2  2  2  33   b   8  piperacillin/tazobactam  2  6  3 11 3  2  3  4  2  2  2   b   68  cefotaxime  2  8  4  5  4  5  4  8   b   35 Continued Activity of sulfametrole/trimethoprim encoded by the sul and dfr genes, respectively. These enzymes compensate for inhibition of their chromosomal counterparts, which are targeted by sulphonamides and trimethoprim, respectively. 6, 7 Sulfametrole/trimethoprim is an alternative sulphonamide/ trimethoprim combination available in several EU countries, including Austria and the Netherlands (the spelling sulfametrol is used in both countries). It is suggested to have pharmacological advantages over sulfamethoxazole/trimethoprim. 8 Several old papers also assert sulfametrole/trimethoprim to have greater antibacterial activity, 9,10 but there is no recent confirmation. The present study therefore compared the activity of sulfametrole against sulfamethoxazole and sulfametrole/trimethoprim against sulfamethoxazole/trimethoprim using current isolates. These principally comprised clinically relevant non-fermenters, but also included multiresistant Enterobacteriaceae and those with the common sulphonamide resistance determinants, sul1 and sul2.
Materials and methods

Test organisms
The non-fermenters and multiresistant Enterobacteriaceae were sent to Public Health England's Antimicrobial Resistance and Healthcare Associated Infections Reference Unit for investigation of resistance between 2008 and 2012. The non-fermenters comprised: 40 S. maltophilia, including 10 previously found to be sulfamethoxazole/trimethoprim resistant; 40 B. cepacia group isolates, including 10 previously found to be sulfamethoxazole/trimethoprim resistant; 20 E. meningoseptica and 20 other chryseobacteria/flavobacteria; 10 Achromobacter spp.; 10 Alcaligenes spp.; and 30 Acinetobacter baumannii. Except for the A. baumannii, most were indicated to be from cystic fibrosis patients. Identification was by MALDI-ToF, by 16S rRNA gene sequencing or with API20NE strips, except for A. baumannii, which was identified by the presence of a bla OXA-51-like gene.
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The multiresistant Enterobacteriaceae comprised 20 isolates with carbapenemases (five each with KPC, NDM, VIM and OXA-48 enzymes, based on PCR detection of the corresponding genes) and 20 with extendedspectrum b-lactamases (ESBLs), based on synergy between cefotaxime and/or ceftazidime and clavulanic acid. To assess the effects of common antifolate resistance determinants, we used a collection of 45 Escherichia coli isolates, comprising 9 fully susceptible to antifolates, 9 with sul1 and trimethoprim resistant, 10 with sul1 and trimethoprim susceptible, 8 with sul2 and trimethoprim resistant and 9 with sul2 and trimethoprim susceptible. Those with sul1 and sul2 were from the collection of Enne et al., 1 who described their characterization; the susceptible isolates were from the collection of McNulty et al.
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Antibiotics and susceptibility tests MICs were determined by CLSI agar dilution using Mueller-Hinton agar (Oxoid, Basingstoke, UK) 13 and the following antibiotics: sulfametrole (Rokitan, Vienna, Austria), sulfamethoxazole and trimethoprim (both from Sigma, Poole, UK), ticarcillin (Sigma) with 2 mg/L clavulanate (Glaxo, Brentford, UK), moxifloxacin (Bayer, Newbury, UK), tigecycline (Pfizer, Sandwich, UK), piperacillin (Sigma) with 4 mg/L tazobactam (Pfizer), cefotaxime (Sigma) and imipenem (Merck, Hoddesdon, UK). Sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim were tested as 19: 1 combinations, with MICs expressed relative to the trimethoprim component. A challenge was that neither the CLSI nor the EUCAST testing has breakpoints for many agents versus non-fermenters. Accordingly, and pragmatically, we adopted: (i) the CLSI breakpoint of 256 mg/L sulfamethoxazole for Enterobacteriaceae for all species for both sulfamethoxazole and for sulfametrole; (ii) the CLSI breakpoint of 8 mg/L trimethoprim for Enterobacteriaceae for all species; (iii) the CLSI breakpoint of 2 mg/L sulfamethoxazole/ trimethoprim for Enterobacteriaceae for all species for both sulfamethoxazole/trimethoprim and sulfametrole/trimethoprim; (iv) the CLSI breakpoints for Acinetobacter/'other non-Enterobacteriaceae' for ticarcillin/ clavulanate, piperacillin/tazobactam and imipenem; (v) 2 mg/L moxifloxacin for non-Enterobacteriaceae (as for levofloxacin) and 1 mg/L for Enterobacteriaceae; and (vi) the FDA breakpoint of 2 mg/L tigecycline for Enterobacteriaceae, for all species.
Control strains comprised E. coli NCTC 10418, ATCC 25922 and ATCC 35218 along with P. aeruginosa ATCC 27853.
Results and discussion
Non-fermenters
The MIC distributions for non-fermenter groups are shown in Table 1 , with direct comparison of sulfametrole versus sulfamethoxazole and sulfametrole/trimethoprim versus sulfamethoxazole/trimethoprim in Figure 1 . Results for sulfametrole closely resembled those for sulfamethoxazole whilst results for sulfametrole/trimethoprim resembled those for sulfamethoxazole/trimethoprim, with MICs mostly identical or one doubling dilution higher for sulfametrole and its combination (Figure 1 ).
Sulphonamides and their combinations were the most broadly active agents against the non-fermenter collections (Table 1) , with 70% -100% susceptibility among all groups except A. baumannii, which are unusual among non-fermenters in their propensity to acquire resistance genes more usually associated with Enterobacteriaceae, carried by plasmids or on resistance islands. 14, 15 It should be stressed that the Burkholderia and S. maltophilia collections-with 60% -75% susceptibility to sulphonamides and their combinations-were loaded with 25% sulfamethoxazole/ trimethoprim-resistant isolates. This loading sought to identify whether sulfametrole/trimethoprim might overcome sulfamethoxazole/trimethoprim resistance-a hypothesis refuted by the results. Sulphonamide combinations would be expected to have more comprehensive activity against unselected isolates; current Public Health England data suggest an 5% resistance rate to sulfamethoxazole/trimethoprim in S. maltophilia (http://www.hpa.org.uk/ hpr/archives/2011/hpr2811.pdf). Mechanisms of resistance were not characterized, but it is known that S. maltophilia can acquire and express sul1 and sul2 determinants, but that these do not account for all observed resistance. 16 We can find no record of antifolate resistance mechanisms having been characterized in Burkholderia spp.
The only other antibiotics to retain broad overall antinon-fermenter activity were: (i) piperacillin/tazobactam, which, however, had poor activity (8% susceptible versus 70% -75% for sulphonamide combinations) against S. maltophilia, which is the most prevalent of these pathogens; and (ii) moxifloxacin, which nevertheless lacked activity against Burkholderia and Achromobacter. Ticarcillin/clavulanate and imipenem had good activity only against Achromobacter and Alcaligenes spp., and cefotaxime only against Alcaligenes spp., whilst tigecycline had scattered activity, with 30% -70% of Achromobacter, Alcaligenes, Chryseobacterium and S. maltophilia susceptible, but with generalized resistance among Burkholderia and Elizabethkingia spp. Tigecycline was the most active antimicrobial against the Acinetobacter panel, with 47% susceptibility compared with 30% -37% for the sulphonamides and their combinations, and negligible rates for other compounds. Livermore et al.
Enterobacteriaceae
Most (80%-95%) isolates of Enterobacteriaceae with ESBLs and carbapenemases were resistant to both of the sulphonamides and their trimethoprim combinations; nevertheless, one Enterobacter cloacae with a KPC carbapenemase and one Klebsiella pneumoniae with OXA-48 enzyme showed some susceptibility The carbapenemase producers were also widely resistant to all the other antibiotics tested except tigecycline; the few that remained susceptible to cefotaxime had OXA-48 enzyme, whereas moxifloxacin susceptibility was scattered among all groups except those with NDM enzymes Most ESBL producers were resistant to all agents except imipenem and tigecycline. Most (95%) of the ESBL producers also appeared susceptible to piperacillin/tazobactam, though this would have fallen to 65% had EUCAST's 8 mg/L susceptibility breakpoint been used rather than the CLSI's 16 mg/L value. These Enterobacteriaceae were not selected on the basis of antifolate resistance and the poor activity of sulphonamides and their combinations almost certainly reflects the fact that ESBL-and carbapenemase-encoding plasmids often also carry sul1 and sul2 along with various dfr genes, which compromise trimethoprim. 17, 18 In particular, sul1 is embedded in type 1 integrons, which are widespread among large enterobacterial plasmids. Nevertheless, occasional multiresistant isolates, including some with carbapenemases, remain susceptible to sulfamethoxazole/trimethoprim, which has been used effectively in such cases. 5,19 -21 The ability of both sul1 and sul2 to confer resistance to sulfametrole as well as sulfamethoxazole was confirmed directly by testing E. coli isolates with and without these genes ( Table 2 ). The results showed that both genes were associated with sulfametrole and sulfamethoxazole MICs of .1024 mg/L compared with Activity of sulfametrole/trimethoprim 1 -128 mg/L for gene-negative isolates. Organisms that had sul1 or sul2 together with trimethoprim resistance determinants were resistant to both sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim, with MICs generally ≥128 mg/L.
Conclusions
We showed that sulphonamide/trimethoprim combinations remain the most active antibacterials against less common non-fermenters other than A. baumannii, and that, against these organisms, sulfametrole and sulfametrole/trimethoprim were mostly as active as sulfamethoxazole and sulfamethoxazole/trimethoprim, respectively, or were one doubling dilution less active. Sulfametrole and sulfametrole/trimethoprim did not overcome resistance to sulfamethoxazole and sulfamethoxazole/trimethoprim in Enterobacteriaceae, refuting old assertions of better activity. These findings do not, of course, diminish the possibility that sulfametrole/ trimethoprim may have other pharmacological and toxicological advantages. 8 The metabolism of sulfametrole is less complicated than that of sulfamethoxazole and does not yield the oxidative products blamed by some authors for sulfamethoxazole/ trimethoprim-associated rashes; nevertheless 7/9 patients who had experienced rashes with sulfamethoxazole/trimethoprim had recurrences when subsequently administered sulfametrole. 8 It is also suggested that the excipients used with intravenous sulfametrole/trimethoprim formulations are better tolerated than those used in some intravenous sulfamethoxazole/trimethoprim preparations, though direct comparative trials are needed. 8 
